Compare TLX & VET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLX | VET |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | Australia | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | N/A | 2004 |
| Metric | TLX | VET |
|---|---|---|
| Price | $10.75 | $11.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $21.13 | $15.00 |
| AVG Volume (30 Days) | 231.9K | ★ 2.9M |
| Earning Date | 08-19-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.06% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.01 |
| Revenue Next Year | N/A | $3.02 |
| P/E Ratio | $150.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.28 | $5.90 |
| 52 Week High | $19.93 | $14.82 |
| Indicator | TLX | VET |
|---|---|---|
| Relative Strength Index (RSI) | 69.28 | 40.61 |
| Support Level | $10.60 | $7.42 |
| Resistance Level | $11.18 | $12.00 |
| Average True Range (ATR) | 0.33 | 0.60 |
| MACD | 0.08 | -0.27 |
| Stochastic Oscillator | 71.73 | 14.57 |
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe while optimizing low-decline oil assets. Its operating segments are: Canada, France, Netherlands, Germany, Ireland, Australia, and CEE, each representing the oil and gas exploration operations at its assets located in these regions. The company mainly derives revenue from the production and sale of petroleum and natural gas. The majority of its revenue is generated from Canada, where the company's operations are mainly focused on the Deep Basin trend in the West Pembina region of Alberta and on the Mica property.